JPMorgan Reinstates WAVE Life Sciences (WVE) at Overweight

September 27, 2024 3:30 AM EDT Send to a Friend
JPMorgan analyst Eric Joseph reinstates coverage on WAVE Life Sciences (NASDAQ: WVE) with a Overweight rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login